🎓Are you looking to pursue a #PhD and make real impact in science? The new RAREFIND #MSCA-COFUND PhD Program offers a unique opportunity to dive into cutting-edge #genetherapy and #celltherapy research with top-tier, interdisciplinary training across 22 leading labs at TIGEM and SR-Tiget.

🚀 Launch your career in advanced gene and cell therapies! 🚀 RAREFIND #MSCA-COFUND #PhD Programme opens its call for applications! 👉Know more and apply now: www.rarefind-cofund.eu #RAREFINDPhD

Join our lab dibernardo.tigem.it for the #ERC-funded project DIMERCIRCUITS at @tigem.bsky.social. We are building synthetic gene circuits to power next-generation gene and cell therapies. We are looking for candidates with a PhD in #SyntheticBiology or related. Apply by email: [email protected]

📢 Global Call for Scientific Talent – Join the #FondazioneTelethon Institutes! We're looking for exceptional scientists to join #TIGEM and #SR-Tiget, two world-class research centers at the forefront of innovation in #genetherapy, #celltherapy, #geneediting, #genomics, and #molecularmedicine.

Back From #ASGCT!!! TIGEM was pleased to take part in the ASGCT Conference 2025, where we had the opportunity to present our latest research and engage with the gene and cell therapy community! @asgct.bsky.social

🌍 Attending #ASGCT2025 in #NewOrleans? Don’t miss this Scientific Symposium hosted by the Coalition of International Gene Therapy Societies: 📌 Clinical Trials Around the Globe 🗓️ [Today, May 16th] 🕗 8:00 AM – 9:45 AM 📍 Room 293–296 #GeneTherapy #ASGCT #AAV #Retina #LiverGeneTherapy #RareDisease

🎗️ It’s MPS Awareness Day. At TIGEM, we stand with patients — especially those with MPS VI (Maroteaux-Lamy syndrome), a rare lysosomal disorder caused by ARSB gene mutations.

📢Applications for SEMM PhD program are now open! 🎉 We have 2 open positions at TIGEM in the PhD program in Systems Medicine. Deadline: June 9th – don’t miss it! Apply here: www.semm.it/education/ho... #PhD #SystemsMedicine #TIGEM #SEMM #PhDOpportunity #BiomedicalResearch #CallForApplications

Excited for the International Mammalian Synthetic Biology Workshop (mSBW2025) — the only conference fully focused on mammalian synthetic biology! 🧬 Meet top experts, including @diegodibi.bsky.social, Genomic Medicine Program Coordinator at TIGEM and part of this year’s Organizing Committee.

Today we mark #InternationalPompeDiseaseDay, raising awareness for this rare genetic disorder. At TIGEM, supported by #FondazioneTelethon, we combine genetics, molecular biology, clinical research, and patient advocacy to advance new therapies —

Excited to share the latest work of Pastore group! Loss of Folliculin drives liver cell damage and cholangiocarcinoma via MiT/TFE activation. 👉 Read the full article: doi.org/10.1038/s414...

🔬 From Sweden to Italy: @andpdb.bsky.social is bringing his expertise in Computational Structural Biology back home! After working at #KTH (Stockholm), he’s now a Staff Scientist at TIGEM, using AI and physics-based models to design hyperactive enzymes that improve gene therapy for rare diseases.

🚀 Exciting moments at #HydeParkCoroglio! Our Prof. Alberto Auricchio, Scientific Director at Tigem in Pozzuoli, took the stage for an inspiring talk.

🔬 AAV-based gene therapy for Stargardt disease is safe and effective in large animal models A work of #IvanaTrapani and #AAVantgardeBio !!! 📄 #ScienceAdvances | doi.org/10.1126/sciadv.adt9354 #GeneTherapy #Ophthalmology #AAV #Stargardt #VisionResearch

🌟New Research Alert🌟 🧠 Cutting-edge neuroscience from De Leonibus' group, now in #NatureCommunications! This study reveals how different doses of D1 dopamine agonists bidirectionally regulate memory capacity via fronto-striatal cAMP/PKA signaling in mice.

📣 We are hiring!!! 📣 Don't miss your chance to join TIGEM and be part of groundbreaking research! 🔬 🚨Exciting Postdoctoral Opportunity in Gene Therapy & Genome Editing! 🚨 👉 www.tigem.it/newsroom/car... 🚨Research Technician in Gene Therapy & Genome Editing🚨 👉 www.tigem.it/newsroom/car...

Here is our latest paper in @commsbio.bsky.social We reveal a two-phase TFEB nuclear shuttling driven by calcium release and mTORC1 inhibition, using microfluidics & quantitative modelling. Kudos to Iacopo Ruolo & [email protected] @tigem.bsky.social www.nature.com/articles/s42...

🚨 The latest study from #NatureCommunications, led by Pasquale Piccolo, systematically evaluated AAV-mediated liver transduction across different fibrosis models.

I am excited to help organize #mSBW2025. I hope you can join me and my lab to explore latest advances in this field. Learn more at www.aiche.org/sbe/conferen...

🌟New Research Alert🌟 🔬 Exciting findings from Galietta's group, published in #JPhysiology! This study uncovers how the apical mucus layer alters drug efficacy in the airway epithelium, impacting CFTR inhibition in cystic fibrosis research. 📖Read here: physoc.onlinelibrary.wiley.com/doi/full/10....

🌟New Research Alert 🌟 🔬 We are thrilled to share a groundbreaking study by De Matteis’s group, published in #LifeScienceAlliance, which uncovers a crucial link between mitochondrial dysfunction and protein aggregation in ALS8. 📖Read the article here: www.life-science-alliance.org/content/8/4/...

🚀 PhD Opportunity – NC-mTORC1 & Genetic Diseases! Join @tigem.bsky.social & Univ. of Naples to explore Non-Canonical mTORC1 signaling in mTORopathies like BHD & TSC!

🚀 Our mission 🧬 Our mission is to push scientific boundaries through cutting-edge research, innovative therapies, and training the next generation of biomedical experts. Learn more: www.tigem.it ✨ #Genetics #RareDiseases #MedicalResearch